Citius Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) was filed on March 28, 2025, by Citius Pharmaceuticals, Inc. (Citius Pharma), an emerging growth company. The report details a material definitive agreement entered into by Citius Oncology, Inc. (Citius Oncology), a subsidiary in which Citius Pharma owns approximately 92% of the outstanding common stock. The filing addresses obligations related to the exclusive license of E7777 (trade name LYMPHIR), a product licensed from Eisai Co., Ltd. via Dr. Reddy's Laboratories.
Key Financial Metrics and Obligations
The filing outlines specific financial obligations arising from the License Agreement following the FDA approval of LYMPHIR in August 2024:
- Total Obligation to Eisai: Approximately $8,233,209.77 in aggregate development and inventory costs.
- Milestone Payment: $5,900,000 triggered by FDA approval in August 2024.
- Inventory Costs: $6,048,052.67 accrued as of December 31, 2024.
- Development Costs (Receivable): $185,317.70 included in financial statements as of December 31, 2024.
- Remaining Expense: $1,999,839.40 scheduled for recognition in the period ended March 31, 2025.
The filing does not provide consolidated revenue, profit, cash flow, or margin data for Citius Pharmaceuticals, Inc. for the current period.
Material Changes and New Agreement
On March 28, 2025, Citius Oncology and Eisai executed a letter agreement amending the original License Agreement to establish a structured payment schedule for the outstanding obligations. This agreement resolves prior payment failures and releases both parties from claims related to those failures, except for breaches of the new letter agreement.
New Payment Schedule:
- First Payment: $2,535,317.77 due on or before July 15, 2025.
- Monthly Payments: $2,350,000 due on the 15th of each of the next four months following the first payment.
- Final Payment: $2,197,892.07 due on or before December 15, 2025.
All obligations accrue interest at a rate of 2% per annum from the original due date until the date of actual payment.
Outlook, Risks, and Management Commentary
The filing indicates that all other terms of the License Agreement remain in full force and effect. The primary risk identified is the potential for future claims arising from a breach of the new letter agreement. Management has secured a release from claims regarding past payment failures, providing a clear path to settle the $8.2 million obligation by the end of 2025.
Key Facts for Investor Verification
- Verify the cash flow impact of the first payment of $2,535,317.77 due in July 2025.
- Confirm the total interest expense that will accrue on the deferred payments at the 2% annual rate.
- Monitor the recognition of the remaining $1,999,839.40 expense in the Q1 2025 financial statements.
- Assess the liquidity position of Citius Oncology to ensure it can meet the monthly $2.35 million payments through December 2025.